Asset
JAPANESE ENCEPHALITIS VIRUS STRAIN SA 14-14-2 ANTIGEN (FORMALDEHYDE INACTIVATED)
VALNEVA SE AMERICAN DEPOSITARY SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00594958 | phase3 | completed | 2006-09-01 | 2007-04-01 | Valneva Austria GmbH | Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51 |
| NCT00596271 | phase3 | completed | 2005-09-01 | 2006-07-01 | Valneva Austria GmbH | Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440 |
| NCT00595309 | phase3 | completed | 2007-12-01 | 2009-10-01 | Valneva Austria GmbH | Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 |
| NCT01559831 | phase1 | withdrawn | 2012-06-01 | 2012-12-01 | Valneva Austria GmbH | Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination |
| NCT00604708 | phase3 | completed | 2005-09-01 | 2006-09-01 | Valneva Austria GmbH | Immunogenicity Study of the Japanese Encephalitis Vaccine IC51 |
FDA applications (0)
This company has no applications containing this asset.